SITC Accomplishment Reportfor 2013An Overview of the Society’s 2012-2015 Strategic Plan Activities and Accomplishments to Date

CollaborateEngage Learn

CollaborateEngage Learn

SITC 2012 – 2015 Strategic Plan Overview

&e Society for Immunotherapy of Cancer (SITC) was established in 1984 to exchange, encourage and promote information about the promise and breakthroughs of biological therapies, including immunotherapy, for patients with cancer. SITC is the world’s leading member society of medical professionals dedicated to advancing cancer immunotherapy through its initiatives, educational sessions and collaborative endeavors. &e Society has become THE forum for innovative discussions in the /eld.

SITC is a 501 (c)(3) non-pro/t society of medical professionals including more than 800 in2uential leaders and scientists engaged in tumor immunology and cancer immunotherapy, including academicians, senior researchers, clinicians, students, government representatives, and industry leaders from around the world. SITC’s members represent 17 medical specialties and are engaged in research and treatment of at least a dozen types of cancer.

As the /eld of cancer immunotherapy continues to expand, the Society realized the importance of convening SITC leaders and sta4 for a strategic planning retreat this past summer to discuss the Society’s current priorities and opportunities on the horizon. &e overarching goal of the retreat was to shape the day-to-day activities of the Society and prioritize e4orts as a part of enacting its 2012-2015 Strategic Plan.

CollaborateEngage Learn

SITC Mission It is the mission of the Society for Immunotherapy of Cancer to improve cancer patient outcomes by advancing the science, development and application of immunotherapy through our core values of interaction/integration, innovation, translation and leadership in the /eld.

Core ValuesInteraction/IntegrationFacilitate the exchange of information and education among basic and translational researchers, clinicians, young investigators, societies and groups sharing the mission of SITC

InnovationChallenge the thinking and seek the best research in the development of cancer immunotherapy

TranslationPromote the application and understanding of cancer immunology and immunotherapy research from the bench to the clinic and back

LeadershipDe/ne what is new and important and e4ectively communicate it to all relevant stakeholders

Areas of FocusEngage Collaborate Learn

SITC 2012 – 2015 Strategic Plan Overview

CollaborateEngage Learn

Collaborate: Expand the Society’s impact and in2uence by establishing relationships with key strategic partners.

Cancer Immunotherapy Trials Network (CITN) – SITC partners with this network of top academic immunologists to provide both /nancial and promotional resources to support the CITN mission.

Agent Prioritization – SITC assisted the CITN with the re-prioritization of immunotherapy agents by connecting them with key players and stakeholders in the /eld.

Immunoscore – SITC continues to lead the progress of this international, retrospective evaluation of immunoscore as a prognostic biomarker for patients with colon cancer.

Interactions with Regulators – SITC is valued by its members for providing a unique forum for interactions with government regulators. SITC has a long-standing relationship with the FDA and is a participating organization in the FDA Cell &erapy Liaison Meetings.

Member of FOCIS – SITC is a member of the Federation of Clinical Immunology Societies (FOCIS), a group of non-pro/t organizations that foster interdisciplinary approaches to understand and treat immune-based diseases with the ultimate goal of improving patient care and outcomes.

SITC partnered with related organizations to expand the reach of cancer immunotherapy:

Overcoming Barriers to Adaptive Immunity in Honolulu, Hawaii (May)

Immunotherapy in Xiamen, China (September)

Immunotherapy in Chicago, Illinois (October)

Speed Networking – In response to feedback from Annual Meeting delegates, this year SITC will host a Speed Networking Event at the Annual Meeting. &is event is made up of a series of one-on-one mini-meetings, giving participants the opportunity to gain a better understanding of recent developments in cancer immunotherapy, identify common interests, strike up potential research collaborations and establish relationships with various stakeholders in the /eld.

World Immunotherapy Council (WIC) - Founded by SITC, this organization was created to liaise with international cancer therapy-focused organizations and interest groups.

CollaborateEngage Learn

Engage: Strengthen the Society and create a more robust membership base by both attracting new members and retaining the active members through the expansion of member bene/ts and cultivation of key constituency groups.

Council for Immunotherapy Education & Outreach (CIEO) - In 2013, SITC established the CIEO to carry out education & outreach activities in support of the Society and its objectives to further the understanding of cancer immunotherapy to a broad audience.

Industry Council - &e Industry Council is comprised of SITC members from the pharmaceutical and biotechnology industries. &e Council’s mission is to push the /eld forward on a worldwide level, create community and present new data, particularly pre-clinical, to a growing and varied constituency.

Public Policy & Advocacy - SITC joined several organizations to issue a “Patient Advisory for Stem Cell &erapy and Medical Tourism.” &e document addresses a number of questions and concerns raised by patients and outlines best practices to assist patients and family members contemplating cell therapy or experimental stem cell procedures.

Membership - SITC continues to experience exponential growth with more than 800 members leading the /eld of cancer immunology and immunotherapy. SITC’s membership base has continued to expand globally and currently has representation from 35 countries indicated in green on the map.

SITC Committees – SITC encourages the participation and involvement of its members on its committees. Currently, over a hundred members serve as volunteers on numerous committees, helping SITC to thrive as a successful non-pro/t organization.

SITC Champion Initiative – Initiated by the SITC Membership Committee the Champion initiative helps to encourage two-way communication between the Society and institutions throughout the country, addresses the need for community education about immunotherapy, as well as disseminate information and builds awareness for SITC’s educational programming and initiatives.

CollaborateEngage Learn

SITC’s reach has expanded through the development of new social media platforms and online communities that have strengthen the relationship between the Society and its members. In addition, SITC has raised awareness for the #eld of cancer immunotherapy through Society-branded press releases that provide updates and present new information and research bene#cial to advancing the #eld.

Recent advancements in society media expansion include:

LinkedIn Job Board – allows SITC members to post jobs in the cancer immunotherapy /elds free of charge. &is assists in the development of the next generation leaders in the /eld and is an added bene/t for early career scientists and student members of SITC.

SITC’s Oncology Tube channel – targets a very speci/c audience of those interested in the treatment of cancer. &rough video interviews with SITC leadership and educational webinars, SITC education is able to reach an extensive, broad audience from around the world.

Educational program slide sets and presentations available on the SITC website – allows for Society members and program attendees to revisit presentations from past SITC educational events and assists in advancing the science and application of cancer immunotherapy.

CollaborateEngage Learn

SITC cultivated young investigators in the #eld of cancer immunotherapy by expanding educational o$erings and increasing opportunities for early career professional to be involved in Society activities and programs.

Early Career Scientist Committee – SITC established the Early Career Scientist Committee to partner with SITC leadership to address the needs of early career scientists in the /elds of immunology and immunotherapy.

Next Generation Leadership Development – SITC has included young investigator representatives on all relevant SITC committees to cultivate the next generation development of cancer immunologists and immunotherapists.

Young Investigator Awards – SITC continues to support ten young investigators’ travel to the Society’s Annual Meeting in order to encourage and engage the next generation of cancer immunotherapy researchers and luminaries.

Photo credits: Michael Hoetzel, DGPh

CollaborateEngage Learn

Learn: Provide education and training about the principles and practice of cancer immunotherapy to be widely recognized as the leading scienti/c voice in the /eld.

Cancer Immunotherapy Clinical Trials (CICT) Workshop – &is two-day workshop outlined the current challenges posed by the development of therapeutic trials in immunotherapy and provided participants with the tools to develop a framework and recommendations on how to design better clinical trials.

Advances in Cancer Immunotherapy (ACI) Regional Series – In 2013, SITC launched an Advances in Cancer Immunotherapy regional program series speci/cally designed to provide education on the principles and clinical application of immunotherapy to clinical oncologists and the entire unit of care. Seven of these CME-certi/ed programs took place in locations across the country.

ACI-IL – Leading into the American Society of Clinical Oncology (ASCO) Annual Meeting, May 31, 2013 Organizers: %omas F. Gajewski, MD, PhD; Justin P. Kline, MD

Organizers: Patrick Hwu, MD; Elizabeth A. Mittendorf, MD, PhD; Padmanee Sharma, MD, PhD

ACI-OH

and in Collaboration with Case Comprehensive Cancer Center. October 4, 2013. Organizers: James H. Finke, PhD; Joseph Baar, MD, PhD; Brian I. Rini, MD

ACI-FL

ACI-FL – In collaboration with Mo9tt Cancer Center, December 7, 2013 Organizers: James Mulé, PhD; Verrich, K. Sondak, MD

ACI-PAACI-PA – In collaboration with University of Pittsburgh Cancer Institute, partner with UPMC, December 7, 2013

Organizers: Lisa H. Butter#eld, PhD; Robert L. Ferris, MD, PhD; Hassane M. Zarour, MD

ACI-WAACI-WA

ACI-WA – In collaboration with Seattle Cancer Care Alliance, December 14, 2013 Organizers: Kim A. Margolin, MD; Walter J. Urba, MD, PhD

ACI-CA

ACI-CA – San Francisco, December 14, 2013 Organizers: Lawrence Fong, MD; Antoni Ribas, MD

SITC Industry Primer – Recognizing a need to provide unbiased immunotherapy support and education to industry, SITC created an Industry Primer program to teach basic principles of cancer immunotherapy with up-to-date information on recent advances in the /eld to this stakeholder group.

CollaborateEngage Learn

SITC continues to position itself as the leading resource for information and education on cancer immunotherapy by developing educational materials and outlets.

Publication of Guidelines on the Use of Cancer Immunotherapy in Melanoma – SITC released the /rst evidence-based consensus statement on tumor immunotherapy for the treatment of patients with melanoma in the US, providing clinicians with expert recommendations for the use of di4erent immunotherapies. With this statement, SITC took a leadership role in addressing the de/ciency in resources for physicians on how to appropriately treat cancer with immunotherapy.

Journal for Immuno"erapy of Cancer

Immunotherapeutic Products for Cancer and FDA’s Role in Product Development and Clinical Evaluation,” “Immune Monitoring Using the Predictive Power of Immune Pro/les,” “Turning T cells On: Epigenetically Enhanced Expression of E4ector T-cell Costimulatory Molecules on Irradiated Human Tumor Cells” and a Society meeting report “Primer on Tumor Immunology and Cancer Immunotherapy.” Additionally, SITC members have taken advantage of the 2013 membership bene/t of free article processing fees when submitting

SITC Publications – &is year, the Society has published four papers including program highlights and meeting summaries.

Workshop, October 24th-25th 2012”

CollaborateEngage Learn

Annual Meeting Highlights – SITC’s Annual Meeting continues to grow, welcoming a record number of delegates this year. Highlights at SITC 2013 include:

Record number of exhibitors at 28th Annual Meeting – As a testament to how SITC gathers all relevant stakeholders in the /eld, the 28th Annual Meeting has attracted a record number of exhibitors, doubling the number from the previous year.

SITC continues to provide live education and training about cancer immunotherapy at SITC 2013:

Immunotherapy™th Annual Meeting

in Checkpoint Blockade: Is PD-L1 Tumor Expression Necessary?

Young Investigator /Early Career Scientist Opportunities at SITC 2013 –

Young Scientists

Industry Forum - SITC 2013 will feature an Industry Forum event to foster dialogue amongst industry members as a SITC constituency group.

CollaborateEngage Learn

Cure... Yeah, we said it!

All proceeds support SITC’s Forward FundTake a photo of you in your t-shirt and you could be featured on the SITC website!

Visit www.sitcancer.org/support/forwardfund for more information

CollaborateEngage Learn

www.sitcancer.org

www.sitcancer.org/support/forwardfund

www.sitcancer/journal